Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-CEACAM5C |
Synonyms | |
Therapy Description |
SGN-CEACAM5C is an antibody-drug conjugate (ADC) comprising a CEACAM5 antibody conjugated to a topoisomerase inhibitor, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2118). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-CEACAM5C | SAR-445953|SAR4 45953|SAR445953|SGN CEACAM5C | SGN-CEACAM5C is an antibody-drug conjugate (ADC) comprising a CEACAM5 antibody conjugated to a topoisomerase inhibitor, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2118). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06131840 | Phase I | SGN-CEACAM5C | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Recruiting | USA | SWE | NLD | GBR | ESP | CAN | 0 |